Leading Companies in the Global Medical Robotics IndustryIntuitive Surgical (ISRG) released its latest quarterly report tonight, which far exceeded market expectations. Itsda Vinci surgical robot system (especially the new generation Gen5) has reached 228 installations in the United States, significantly surpassing the market expectation of 201 units. In the latest fiscal quarter,the number of da Vinci surgeries increased by 19%, and Ion surgeries increased by 52%. CEO David Rosa emphasized that system upgrades and strong international installation demand drove a 23% revenue growth. The latest operational performance of Intuitive Surgical indirectly verifies the high growth of the global medical robotics industry. I have been paying close attention to this field recently, and today I will discuss the current global and domestic development of the industry, as well as four domestic companies within my scope (three A-share companies and one Hong Kong stock company), with a focus on eight key companies in the US market over the weekend.
1. Overview of Global Medical Robotics Industry Development
The global medical robotics market is experiencing unprecedented growth, but due to differences in statistical criteria, coverage, and definition standards, there are significant discrepancies in market size data provided by various research institutions. According to the latest data from Persistence Market Research, the global medical robotics market size is projected to reach $10.3 billion by 2025 and is expected to reach $32.2 billion by 2032, with a compound annual growth rate (CAGR) of 17.7%. Mordor Intelligence data indicates that the market size will be $15.47 billion by 2025 and will reach $32.67 billion by 2030, with a CAGR of 16.13%.The data discrepancies mainly stem from different institutions’ interpretations of the definition of medical robots; some only count surgical robots, while others include rehabilitation robots, nursing robots, pharmacy automation robots, and other broader fields.
From a segmented market structure perspective, surgical robots remain the largest segment, accounting for 26.9% of the market share in 2024. Although rehabilitation robots currently have a smaller market share, they are growing the fastest, expected to grow at a CAGR of 18.2% by 2030. In terms of application areas, general surgery occupies 29.8% of the market share, while neurosurgery applications are expected to become the fastest-growing application area with a CAGR of 22.7%.
In terms of component composition, instruments and accessories account for 51% of the market share, reflecting that the medical robotics industry follows a “razor-and-blade” business model, generating continuous revenue through the sale of high-value disposable instruments and accessories. Service businesses are also growing rapidly, with a CAGR of 18.71%, including software, analytics, training, and on-site maintenance services.
The global medical robotics market exhibits significant regional development imbalances. North America, with its strong technological innovation capabilities, comprehensive healthcare system, and ample funding, continues to maintain a leading position globally. According to the latest data, North America is expected to account for 36-51% of the market share in 2024 (with slight variations in statistics from different institutions). The United States, as the largest single market globally, leads the world in both the installation and surgical volume of surgical robots, with Intuitive Surgical’s da Vinci system alone completing over 1.75 million surgeries in the US.
The European market ranks second, accounting for approximately 21-30% of the market share. The development characteristics of the European market emphasize a balance between technological innovation and healthcare quality, with countries like Germany, the Netherlands, and Sweden leading in the clinical application of surgical and rehabilitation robots. Germany’s mandatory minimum surgical volume policy has driven hospitals to invest in robotic systems, while the UK’s NICE (National Institute for Health and Care Excellence) regulates the application of robotic technology through cost-effectiveness assessments to ensure rational resource allocation.
The Asia-Pacific region is becoming a new engine for growth in the global medical robotics market, expected to grow at a CAGR of 18% by 2030. China, as the largest market in the Asia-Pacific region, is projected to account for nearly 30% of the global market share by 2025, becoming a key driver of global market growth. Japan has a technological advantage in rehabilitation and nursing robots, with its government subsidizing exoskeleton robots for post-stroke rehabilitation through national insurance programs. South Korea is actively exploring the Robot-as-a-Service (RaaS) model, reducing the initial investment threshold for hospitals through subscription models.
Other regions such as Latin America, the Middle East, and Africa currently have a small market share, but with improvements in healthcare infrastructure and increased accessibility to technology, they are expected to become important sources of future growth. Particularly in emerging economies like India and Brazil, the medical robotics market is showing rapid growth, mainly benefiting from population growth, increased disease burden, and rising demand for medical technology.
The rapid development of artificial intelligence technology is profoundly changing the technological landscape of the medical robotics industry. AI algorithms can analyze vast amounts of data, providing intelligent decision support for robotic systems, helping surgical robots learn from past surgeries, and continuously improving surgical precision and efficiency. By 2025, medical robots will focus more on patient interaction, achieving more humanized services through technologies such as voice recognition and emotional analysis. At the same time, AI technology endows medical robots with advanced perception, decision-making, and execution capabilities, enabling them to perform intelligent diagnosis and precise surgeries more accurately in complex medical environments.
The popularization of 5G communication technology brings new development opportunities for medical robots. The low latency and high bandwidth characteristics of 5G networks make remote surgeries possible, allowing high-quality medical resources to break geographical limitations and provide high-quality medical services to patients in remote areas. With the integration of 5G and edge computing, remote robotic surgeries will gradually become a reality, which can not only address the uneven distribution of medical resources but also improve the accessibility and efficiency of surgeries.
The application of digital twin technology is revolutionizing the planning and execution of surgeries. A digital twin is a highly detailed, real-time virtual model of a patient’s anatomical structure, created by integrating MRI, CT, ultrasound, and other imaging data, allowing surgeons to conduct precise surgical simulations before actual surgeries. In robotic surgeries, digital twin technology enables accurate preoperative planning, risk assessment, and even surgical rehearsals in a simulated environment. When synchronized with robotic systems, it can guide intraoperative decisions, optimize tool paths, and minimize tissue damage.
Advancements in sensor technology provide medical robots with more precise perception capabilities. The next generation of medical robots is equipped with various advanced sensors, including force sensors, visual sensors, and tactile sensors, which can perceive changes in the surgical environment in real-time, providing doctors with richer feedback information. For example, Intuitive Surgical’s latest da Vinci 5 system introduces force feedback technology, which can display the force applied by instruments in real-time, ranging from 0 to 6.5 Newtons, helping doctors better control surgical force and avoid tissue damage.
Breakthroughs in robotic motion control technology enable medical robots to perform more complex and precise movements. Modern medical robots generally adopt multi-degree-of-freedom robotic arm designs, such as Vicarious Surgical’s robots, which have nine degrees of freedom per arm, far exceeding the seven degrees of freedom of traditional robots, allowing for 360-degree omnidirectional operation. At the same time, advanced motion control algorithms can achieve sub-millimeter positioning accuracy, ensuring the precision and safety of surgeries.
The aging population is the core driving force behind the growth of the medical robotics market. The proportion of the global population aged 65 and older has risen from 9.3% in 2020 to 10.8% in 2024, with developed countries like Japan and Germany having elderly populations exceeding 20%. In China, by the end of 2023, the population aged 60 and above reached 297 million, accounting for 21.1%, with those aged 65 and above numbering 217 million, accounting for 15.4% of the total population, officially entering a moderately aging society. The surge in complex surgical demands due to chronic diseases and tumors in an aging society has led patients to pay more attention to the thoroughness and safety of surgeries, with a continuous preference for “minimally invasive, precise, and rapid recovery” technologies.
The growing demand for minimally invasive surgeries provides strong momentum for the medical robotics market. Compared to traditional open surgeries, robot-assisted surgeries have significant advantages such as less trauma, less bleeding, faster recovery, and fewer complications, making them increasingly favored by patients and doctors. Particularly in fields such as urology, gynecology, orthopedics, and thoracic surgery, robotic surgeries have become the preferred option for many complex procedures. Data shows that in 2024, the da Vinci surgical system completed approximately 2.683 million surgeries globally, a 17.3% increase from 2.286 million in 2023.
The pressure to control healthcare service costs is driving the application of automation technologies. Faced with rising healthcare costs, healthcare systems in various countries are seeking solutions to improve efficiency and reduce costs. Medical robots can significantly lower overall healthcare costs by improving surgical precision, shortening surgery times, and reducing complications. Research indicates that although the initial investment in robotic systems is high, they can achieve cost-effectiveness in the long run by improving surgical efficiency, reducing hospital stays, and lowering complication rates.
The growing shortage of medical professionals is increasingly highlighting the demand for automated surgical equipment. Globally, the number of qualified surgeons is far from meeting the growing surgical demand, especially in specialized fields such as neurosurgery and cardiac surgery, where professionals are extremely scarce. Medical robots can enable more doctors to perform complex surgeries by standardizing surgical processes and reducing surgical difficulty, effectively alleviating the talent shortage issue.
2. Overview of the Latest Developments in the Domestic Medical Robotics Market in China
The Chinese medical robotics market is in a phase of explosive growth, with rapid market expansion. According to predictions from several authoritative institutions, the market size of medical robotics in China is expected to reach 14.94-23.49 billion RMB by 2025 (with differences in statistical criteria among institutions). The China Business Industry Research Institute predicts that the market size will increase to 14.94 billion RMB by 2025 and is expected to exceed 70 billion RMB by 2030, with an annual compound growth rate exceeding 20%. In terms of market structure, surgical robots dominate, with a projected market size of 11.03 billion RMB by 2025, accounting for 74% of the overall market, with an annual compound growth rate of 34.5%. Rehabilitation robots, as the second-largest segment, are also showing strong growth momentum, especially lower limb exoskeleton robots, which are expected to exceed 3.5 billion RMB by 2025, with a compound annual growth rate exceeding 40%. The nursing robot market is also growing rapidly, with approximately 13,000 nursing robots in the country by 2024, a year-on-year increase of 35%, serving 1.28 million patients.
The rapid growth of the Chinese medical robotics market is mainly driven by several factors: first, the huge demand brought about by an aging population. As the aging process in China deepens, the incidence of chronic diseases and tumors continues to rise, leading to an increasing demand for precision medicine and minimally invasive surgeries. Second, there is a clear trend of upgrading medical consumption, with patients continuously raising their expectations for the quality of medical services and being willing to pay higher costs for better treatment outcomes. Third, the increasingly prominent issue of uneven distribution of medical resources can be addressed through medical robotics technology, improving the accessibility and standardization of medical services.
From a regional development perspective, the Chinese medical robotics market exhibits significant regional concentration characteristics. First-tier cities and developed regions such as Beijing, Shanghai, Guangzhou, and Shenzhen are leading in terms of technological innovation, clinical application, and market size. Particularly, Beijing, as the core area for medical robotics research and development in China, has gathered top research institutions and clinical application units such as Tianzhihang and Jishuitan Hospital. Shanghai has advantages in the field of laparoscopic surgical robots, with many minimally invasive robot companies headquartered there.
Chinese medical robotics companies have made a series of important breakthroughs in technological innovation, with some products reaching or approaching international advanced levels. In the field of laparoscopic surgical robots, the Tumai system from Minimally Invasive Robotics stands out. This system uses a self-developed robotic arm system with seven degrees of freedom and sub-millimeter positioning accuracy, demonstrating operational flexibility comparable to the da Vinci system in hepatobiliary and pancreatic surgeries. In February 2025, the Tumai single-port laparoscopic surgical robot received NMPA approval for market launch, marking a significant breakthrough in China’s single-port laparoscopic surgical robot technology.
In the field of orthopedic surgical robots, Tianzhihang, as a leading domestic enterprise, has seen its Tianji series products achieve sub-millimeter positioning accuracy and localized pricing strategies (with a single device priced between 8-12 million RMB), resulting in a year-on-year increase of 17% in penetration rates in secondary hospitals. In 2024, Tianzhihang’s orthopedic surgical robot installations exceeded 420 units, achieving a 39% market share in the domestic orthopedic segment, with over 39,000 surgeries completed in the year, a 62.5% increase from 24,000 in 2023.
The vascular interventional surgical robot is another important area of technological breakthroughs in China’s medical robotics. The R-ONE vascular interventional robot from Minimally Invasive Robotics has demonstrated outstanding performance in precise vascular path control, remote operation, and radiation protection. This system completed the first domestic 5G remote vascular interventional surgery in 2024, marking China’s leap from following to leading in this field. In 2024, R-ONE vascular interventional robot received eight domestic orders and 18 global orders, with expectations to increase domestic orders to 15 after winning a bid from a leading hospital in Shanghai in 2025.
Significant progress has also been made in the field of rehabilitation robots. Weisi Medical, as the only FDA-certified lower limb walking exoskeleton manufacturer in China, has seen its products enter over 8,000 medical institutions, achieving an 18% market share. The company’s lower limb exoskeleton robots experienced rapid growth in 2024, with a 41% increase in shipments and terminal prices dropping to the 800,000 RMB range, greatly improving product accessibility. Xiangyu Medical is a leader in the brain-machine interface rehabilitation robot field, with its globally first non-invasive brain-machine interface exoskeleton achieving “thought-driven” control, with an accuracy rate of 95% in recognizing brain signals.
In terms of industrialization progress, Chinese medical robotics companies have demonstrated strong commercialization capabilities. By October 2025, Minimally Invasive Robotics had accumulated over 170 core product orders in laparoscopic, orthopedic, and vascular interventional fields, with the Tumai laparoscopic surgical robot achieving over 100 global commercial orders and nearly 80 global installations, maintaining the top position among domestic brands. Tianzhihang’s order volume in the first quarter of 2025 increased by 210% year-on-year, indicating strong market demand.
The competitive landscape of the Chinese medical robotics market is undergoing profound changes, showing a development trend of “one strong and many strong”. In the field of surgical robots, imported brands still dominate, particularly Intuitive Surgical’s da Vinci system, which holds a leading position in the Chinese market due to its first-mover advantage and technological accumulation. However, domestic brands are rapidly rising, with market shares continuously increasing. Data shows that the market share of domestic laparoscopic robots has risen from 32.61% in 2023 to 48.89% in 2024, indicating a strong trend of import substitution.
In the orthopedic surgical robot segment, the competitive landscape remains relatively stable, with Tianzhihang maintaining its leading position due to its technological advantages and market first-mover advantage. Data from the first three quarters of 2024 shows that Tianzhihang, Stryker, Medtronic, and Jianjia Medical rank among the top four in market share, but the concentration ratio (CR4) has decreased from 88.25% in 2023 to 73.52%, reflecting intensified competition due to the increase in new entrants. Specifically, in the joint surgical robot market, Tianzhihang, Stryker, and Jianjia Medical rank among the top three, with a CR4 of 84.75%; in the spinal surgical robot market, Tianzhihang and Medtronic dominate, with a CR4 as high as 93.56%; and in the trauma surgical robot market, Tianzhihang holds an absolute advantage with a market share of 97.30%.
In terms of technological development trends, Chinese medical robotics is moving towards intelligence, integration, and remote operation. The integration of AI technology enables medical robots to achieve more precise surgical planning and real-time decision support. For example, at the 2025 CMEF exhibition, Ge Rui Technology launched the fifth-generation intraoperative C-arm CT intelligent imaging system “Newton 3D” and the “Newton” endoscopic minimally invasive surgical robot, showcasing a new paradigm of surgical operations from precise operation to full-process intelligence.
The application of 5G technology is driving the development of remote surgeries. The R-ONE vascular interventional robot from Minimally Invasive Robotics has already achieved 5G remote surgical capabilities, with the proportion of remote surgeries expected to increase from 2.1% in 2023 to 15% by 2030. This technological breakthrough will greatly enhance the accessibility of high-quality medical resources, especially for remote areas with relatively scarce medical resources.
Cost control has become an important factor driving market development. With technological advancements and large-scale production, the costs of medical robots are rapidly decreasing. By 2025, the average price of laparoscopic surgical robots is expected to decrease by 42% compared to 2020, driving the penetration rate in secondary hospitals to 18%. In the rehabilitation robot field, the terminal price of lower limb rehabilitation robots has already dropped to the 800,000 RMB range, greatly improving product market acceptance.
3. Key Domestic Medical Robotics Companies
1. Tianzhihang (688277): Leader in Orthopedic Surgical Robots
Tianzhihang is the absolute leader in China’s orthopedic surgical robot field, leading in technological innovation, market share, and commercialization capabilities. Founded in 2001, it is the first domestic and fifth globally to obtain medical robot registration licenses, listed on the Sci-Tech Innovation Board in 2020, becoming the “first medical robot stock on the Sci-Tech Innovation Board”. After more than twenty years of technological accumulation and market cultivation, Tianzhihang has established a complete product system and service network for orthopedic surgical robots.
In terms of technical strength, Tianzhihang has deep technical accumulation in orthopedic surgical navigation robots. The company’s core product, the Tianji series orthopedic surgical robot, incorporates several self-developed key technologies, including a high-precision optical tracking system, six-degree-of-freedom robotic arms, and intelligent surgical planning software. Notably, its self-developed optical tracking system compresses positioning time to 2.3 seconds, improving efficiency by 40% compared to imported devices, showcasing strong technological advantages. In terms of positioning accuracy, the Tianji series products achieve sub-millimeter accuracy, meeting the precise positioning needs of various orthopedic surgeries such as spinal, joint, and trauma surgeries.
In terms of market performance, Tianzhihang has shown strong growth momentum. In 2024, the company exceeded 420 installations of orthopedic surgical robots, achieving a 39% market share in the domestic orthopedic segment, maintaining its leading market position. More importantly, the company’s surgical volume has rapidly increased, completing over 39,000 surgeries in 2024, a 62.5% increase from 24,000 in 2023. In the first quarter of 2025, the company’s order volume increased by 210% year-on-year, indicating strong market demand.
In terms of product layout, Tianzhihang has formed a product system covering all orthopedic fields, including spinal, joint, and trauma surgeries. In the spinal surgical robot field, the company holds an absolute advantage, with a market share of 97.30%. In the joint surgical robot market, the company competes with international giants such as Stryker and Jianjia Medical, ranking among the top three in market share. In the trauma surgical robot field, the company also holds a dominant position. This comprehensive product line not only enhances the company’s market competitiveness but also provides customers with one-stop solutions.
In terms of commercialization capabilities, Tianzhihang has successfully opened up the secondary hospital market through localized pricing strategies. The company’s products are priced between 8-12 million RMB, which provides a significant price advantage compared to imported products, enabling secondary hospitals to afford the investment in robotic systems. At the same time, the company offers comprehensive services such as training, maintenance, and technical support to ensure hospitals can effectively use the equipment, improving surgical efficiency and quality.
In terms of technological innovation, Tianzhihang continues to increase R&D investment, continuously launching new products and technologies. The company has made significant breakthroughs in 5G remote surgical technology, achieving a coverage rate of 35% in tertiary hospitals with its orthopedic navigation robot. Additionally, the company has conducted extensive R&D work in AI-assisted surgical planning, intraoperative real-time navigation, and postoperative effect evaluation, continuously enhancing the intelligence level of its products.
In terms of investment value, Tianzhihang has several outstanding advantages: first, high technical barriers, with multiple core technologies and patents in the orthopedic surgical robot field, forming a high entry threshold; second, a solid market position, as the pioneer and leader in domestic orthopedic surgical robots, the company has established a strong brand influence and customer base; third, significant growth potential, with the aging population and upgrading medical consumption driving huge growth potential in the orthopedic surgical robot market; fourth, strong policy support, as a representative of domestic high-end medical equipment, the company will fully benefit from national policy support for the medical robotics industry.
2. Weisi Medical (688580): Leader in Rehabilitation Robots
Weisi Medical is a leading enterprise in China’s rehabilitation robot field, leading in high-end rehabilitation devices such as lower limb exoskeleton robots and brain-machine interface rehabilitation equipment. Founded in 2001 and headquartered in Nanjing, it was listed on the Sci-Tech Innovation Board in 2020 and is one of the earliest companies focused on the R&D, production, and sales of rehabilitation medical devices. After more than twenty years of development, Weisi Medical has established a complete product system covering various fields such as rehabilitation therapy, rehabilitation training, and rehabilitation nursing.
In terms of technical advantages, Weisi Medical has several core technologies in the rehabilitation robot field. The company is the only domestic lower limb walking exoskeleton manufacturer certified by the FDA, which fully demonstrates the technical level and safety of its products. The company’s lower limb exoskeleton robot adopts advanced bionic design concepts, simulating the natural movement patterns of the human lower limbs, helping paraplegic patients achieve basic functions such as standing and walking. Clinical data shows that the company’s products have covered over 11,000 patients, accumulating rich clinical application experience.
In terms of market performance, Weisi Medical has shown strong growth. In 2024, the company’s rehabilitation robot business revenue increased by 127%, indicating strong market demand for its products. In terms of market share, the company’s lower limb exoskeleton robot has an 18% market share, ranking among the industry leaders. More importantly, the company’s products have entered over 8,000 medical institutions, with insurance coverage increasing to 30%, greatly improving product accessibility.
In terms of product layout, Weisi Medical has formed a product system centered on rehabilitation robots, covering various rehabilitation technologies such as electrical stimulation therapy, magnetic stimulation therapy, and biofeedback therapy. In the rehabilitation robot field, the company not only has lower limb exoskeleton robots but is also developing upper limb rehabilitation robots and intelligent rehabilitation training systems. Particularly in the brain-machine interface rehabilitation equipment field, the company is developing brain-controlled upper limb rehabilitation robots and brain-controlled lower limb exoskeleton robots, aiming to address the issue of insufficient patient participation in traditional rehabilitation.
In terms of commercialization progress, Weisi Medical achieved significant breakthroughs in 2024. The company’s lower limb exoskeleton robot shipments increased by 41%, with terminal prices successfully dropping to the 800,000 RMB range, providing a significant price advantage compared to imported products. This price breakthrough allows more medical institutions and patients to afford rehabilitation robots, greatly expanding the market space. At the same time, the company has collaborated with insurance departments to include some products in the insurance reimbursement scope, further enhancing product competitiveness.
In terms of technological innovation, Weisi Medical continues to increase R&D investment, with a 25% increase in R&D investment in 2024. The company has conducted extensive exploration in cutting-edge technology fields such as brain-machine interface technology, AI-assisted rehabilitation training, and virtual reality rehabilitation. Particularly in brain-machine interface technology, the company is developing non-invasive brain-machine interface rehabilitation devices that can control rehabilitation devices through the collection and analysis of brain signals, bringing new hope to paralyzed patients.
In terms of investment value, Weisi Medical has several core advantages: first, technological leadership, as the only domestic lower limb walking exoskeleton manufacturer certified by the FDA, the company is at the forefront of technology; second, broad market prospects, with rapid growth in demand for rehabilitation robots driven by the aging population and increased awareness of rehabilitation; third, a rich product line, as the company not only dominates the lower limb exoskeleton field but is also actively laying out upper limb rehabilitation and brain-machine interface fields, showing good growth potential; fourth, significant cost advantages, with the company’s product prices being about half of imported products, making it highly competitive in the trend of domestic substitution.
3. Xiangyu Medical (688626): Pioneer in Brain-Machine Interface Rehabilitation
Xiangyu Medical is a leading enterprise in the rehabilitation medical device industry in China, leading in the field of brain-machine interface rehabilitation robots. Founded in 2002 and headquartered in Anyang, Henan, it was listed on the Sci-Tech Innovation Board in 2021 and is one of the companies with the most complete product lines in the domestic rehabilitation medical device industry. After more than twenty years of development, Xiangyu Medical has established a full industrial chain layout covering rehabilitation therapy, rehabilitation training, rehabilitation nursing, rehabilitation aids, rehabilitation assessment, and traditional Chinese medicine treatment across ten categories, 55 series, and thousands of products.
In terms of technological innovation, Xiangyu Medical has made significant breakthroughs in brain-machine interface rehabilitation robots. The company’s development of the world’s first non-invasive brain-machine interface exoskeleton has achieved “thought-driven” functionality, with a brain signal recognition accuracy rate of 95%, placing it at the forefront internationally. This system can recognize patients’ movement intentions by collecting and analyzing their brain signals, converting them into corresponding action commands to help paralyzed patients regain basic motor functions. This non-invasive technology avoids the risks and pain associated with traditional invasive brain-machine interfaces, offering better safety and acceptability.
In terms of product layout, Xiangyu Medical has formed a product system focused on rehabilitation robots, based on traditional rehabilitation devices. In the rehabilitation robot field, the company not only has brain-machine interface exoskeletons but is also developing portable assistive walking robots and intelligent rehabilitation training systems. Particularly, the portable assistive walking robot is expected to be launched in 2025, featuring a small size, lightweight, and easy operation, meeting patients’ needs for rehabilitation training at home. In the traditional rehabilitation device field, the company’s products cover various aspects such as physical therapy and speech therapy, providing one-stop product solutions for medical institutions.
In terms of market performance, Xiangyu Medical has shown steady but insufficient high growth. In the mid-2025 report, the company’s revenue increased by 6.3% year-on-year. The company continues to focus on technological innovation, with a 25% increase in R&D investment in 2024, demonstrating its commitment to technological innovation and confidence in future development.
In terms of technological development strategy, Xiangyu Medical is actively promoting the deep integration of brain-machine interface technology and rehabilitation robots. The brain-controlled upper limb rehabilitation robot and brain-controlled lower limb exoskeleton robot being developed aim to address the issue of insufficient patient participation in traditional rehabilitation. Through brain-machine interface technology, patients can directly control rehabilitation devices through “thoughts”, greatly enhancing the initiative and fun of rehabilitation training. At the same time, the company is exploring the integration of virtual reality technology into rehabilitation training, using immersive virtual environments to enhance rehabilitation effects.
In terms of commercialization prospects, Xiangyu Medical’s brain-machine interface rehabilitation robots have huge market potential. With the aging population and rising incidence of strokes, the number of paralyzed patients is continuously increasing, leading to an urgent demand for rehabilitation treatment. Traditional rehabilitation mainly relies on therapists’ techniques and simple rehabilitation devices, which are inefficient and limited in effectiveness. The emergence of brain-machine interface rehabilitation robots provides a new solution to this problem. It is expected that with continuous technological maturity and cost reduction, brain-machine interface rehabilitation robots will enter a period of rapid development.
In terms of investment value, Xiangyu Medical has several unique advantages: first, technological leadership, with globally pioneering technology in brain-machine interface rehabilitation robots, creating strong technical barriers; second, product differentiation, as brain-machine interface rehabilitation robots have higher technical content and added value compared to traditional rehabilitation devices, allowing for higher profit margins; third, large market space, with sustained growth in demand for high-end rehabilitation equipment as people’s awareness of rehabilitation treatment increases and their payment capabilities improve; fourth, a complete industrial chain, enabling better cost control and quality assurance from R&D to production to sales.
4. Minimally Invasive Robotics (02252.HK): Versatile Leader in Domestic Surgical Robots
Minimally Invasive Robotics, as a core stock in the Hong Kong medical robotics sector, is one of the few companies that have commercialized surgical robots in multiple subfields, covering high-end surgical areas such as laparoscopic, orthopedic, and vascular interventional robots. Its technological strength and commercialization progress are among the top tier of domestic brands, serving as a core force in promoting domestic substitution in China’s medical robotics. The company leverages the resource accumulation of Minimally Invasive Medical Group to build significant competitive advantages in core technology R&D, clinical collaboration, and global market expansion.
The company has achieved technological breakthroughs in various types of surgical robots, with some core performance indicators reaching international advanced levels. In the field of laparoscopic surgical robots, the core product Tumai laparoscopic surgical robot adopts a self-developed seven-degree-of-freedom robotic arm system, achieving sub-millimeter positioning accuracy and demonstrating operational flexibility comparable to the da Vinci system in complex surgeries. In February 2025, the Tumai single-port laparoscopic surgical robot received NMPA approval for market launch, becoming the first single-port laparoscopic robot product approved in China, filling a domestic technological gap, and its ability to perform multi-organ surgeries through a single 2-3 cm incision further reduces surgical trauma.
The R-ONE vascular interventional robot in the vascular interventional field exhibits globally leading technological characteristics, integrating precise path control, remote operation, and radiation protection. In 2024, it successfully completed the first domestic 5G remote vascular interventional surgery, marking China’s leap from following to leading in this field. This system can physically isolate doctors from the operating table, reducing radiation exposure by over 90%, addressing core safety issues in traditional interventional surgeries.
The Honghu orthopedic surgical robot in the orthopedic field covers multiple scenarios such as spinal and joint surgeries, with its self-developed optical navigation system achieving a positioning error of less than 0.8 mm. In clinical validation in 2024, the accuracy rate of assisted spinal screw implantation surgeries reached 98.7%, exceeding the 92.3% of traditional surgeries, and the average surgical time was shortened by 40 minutes.
The company has built the most comprehensive surgical robot product pipeline in China, forming a “3+N” strategic layout: three core mature products (laparoscopic, vascular interventional, orthopedic) have entered the commercialization stage, while N reserve products (such as neurosurgery and gynecology robots) are in clinical or R&D stages, covering over 80% of high-value surgical scenarios.
|
Product Category |
Core Product |
Commercialization Stage |
Key Advantages |
|
Laparoscopic Surgical Robot |
Tumai Multi-port / Single-port |
Commercialized |
First in China for single-port technology, covering multiple departments such as hepatobiliary and gynecology |
|
Vascular Interventional Robot |
R-ONE |
Commercialized |
Supports 5G remote operation, reducing doctors’ radiation exposure by over 90% |
|
Orthopedic Surgical Robot |
Honghu |
Late Clinical Stage |
Applicable to spinal/joint surgeries, with navigation positioning error < 0.8mm |
|
Neurosurgery Robot |
NeuroMaster |
Clinical Stage |
Integrates intraoperative imaging navigation, applicable to minimally invasive brain surgeries |
|
Gynecological Surgical Robot |
Prototype |
R&D Stage |
Single-port minimally invasive design, reducing postoperative scars and recovery time |
This comprehensive layout not only reduces the market risk of a single product but also creates a technological synergy effect. For example, the robotic arm technology of laparoscopic robots can be transferred to orthopedic products, and the remote control technology of vascular interventions can be reused in neurosurgery, continuously strengthening technological barriers.
The company’s commercialization process has entered an explosive period, with core product installations and order volumes achieving rapid growth. By October 2025, the cumulative comprehensive order volume of the three core products (laparoscopic, orthopedic, vascular interventional) exceeded 170 units, with the Tumai laparoscopic robot achieving over 100 global commercial orders and nearly 80 global installations, maintaining the top position among domestic brands, with its market share in the domestic laparoscopic robot market increasing from 18% in 2023 to 27% in 2024.
In terms of market penetration, the company has achieved coverage in all 31 provinces and cities nationwide, with an installation rate of 62% in top hospitals in first-tier cities, including batch purchases of the Tumai system by top medical institutions such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital. In the first half of 2025, the company won the procurement project for vascular interventional robots from six leading hospitals in Shanghai, with expectations for domestic orders of R-ONE to increase from eight in 2024 to 15, a year-on-year increase of 87.5%.
In terms of international expansion, the Tumai system has obtained EU CE certification, completing its first overseas clinical surgery at the University Hospital of Munich in Germany in 2024, and starting its layout in the Southeast Asian market in 2025, with the first device already installed at Singapore General Hospital, marking the beginning of its global journey.
The investment value of Minimally Invasive Robotics is reflected in three core advantages. First, deep technological barriers: the company holds over 1,500 global patents, with core technologies such as single-port robotic arms and remote interventional control being independently developed, breaking the technological monopoly of foreign companies like Intuitive Surgical, aligning with the policy direction of the “14th Five-Year Plan” for the medical equipment industry, which aims for a localization rate of over 70% for key components. Second, strong commercialization capabilities: it is the first domestic surgical robot company to achieve profitability across multiple products, with a 120% year-on-year revenue growth in the first half of 2025, and the “equipment + consumables” business model gradually taking shape, with the single-use instruments of the Tumai system priced at around 5,000 RMB, generating annual consumable revenue that can reach 30% of the equipment price, demonstrating sustainable monetization capabilities. Third, dual driving forces from policies and markets: benefiting from the pilot policy for insurance payments for domestic surgical robots (to be implemented in 2025), it is expected to increase the penetration rate in secondary hospitals from the current 8% to 25% by 2027; at the same time, the wave of domestic substitution in the global surgical robot market provides the company with vast opportunities, with the potential for domestic market share to rise to 35% in the next three years, corresponding to a revenue scale expected to exceed 5 billion RMB.
From my personal understanding, Minimally Invasive Robotics is relatively unique in the domestic medical robotics industry. If the industry explodes in the future, I will prioritize considering it from an investment perspective. Currently, I am only tracking the technological and product developments of various companies in the domestic medical robotics industry, without holding any positions or making investment recommendations.